Publications by authors named "Martin Blogg"
Article Synopsis
- - The study aimed to evaluate the effectiveness of fezolinetant in treating moderate-to-severe menopause-related vasomotor symptoms (VMS) by analyzing patient responses and determining if improvements were significant on an individual patient basis.
- - Researchers utilized data from two phase 3 trials, identifying "responders" based on various reductions in VMS frequency and changes in patient-reported outcomes at 4 and 12 weeks.
- - Results showed that a higher percentage of patients taking fezolinetant experienced substantial reductions in VMS compared to those on placebo, indicating its potential as an effective treatment for menopausal symptoms.
BACKGROUND Long-term real-world outcomes data for kidney transplant recipients (KTRs) converting from immediate-release tacrolimus (IRT) to prolonged-release tacrolimus (PRT) are limited. MATERIAL AND METHODS A retrospective, non-interventional review of adult KTRs treated with PRT for ≥1 month was conducted in Germany. Data were extracted from time of transplant (2008-2014) to 2018.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate how fezolinetant treatment impacts health-related quality of life in women aged 40 to 65 with moderate-to-severe vasomotor symptoms (VMS), using data from the SKYLIGHT 1 and 2 studies.
- A total of 1,022 women were randomly assigned to receive either fezolinetant or a placebo over 12 weeks, followed by a 40-week extension for those who completed the study.
- Results showed that those receiving fezolinetant had significant improvements in quality of life and work productivity, with many reporting their VMS symptoms were "much better" compared to the placebo group.
Background: Anemia is prevalent among patients with chronic kidney disease (CKD), yet current evidence indicates that treatment may not adhere to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. We aimed to document the management of patients with non-dialysis-dependent (NDD)-CKD receiving erythropoiesis-stimulating agent (ESA) therapy in Europe.
Methods: This retrospective, observational study extracted information from medical records in Germany, Spain, and the UK.
Unlabelled: Prolonged-release tacrolimus (PRT) may offer improved outcomes after kidney transplantation compared with immediate-release tacrolimus (IRT). However, data on outcomes beyond 5-y posttransplantation are lacking.
Methods: A retrospective, noninterventional chart review study examined long-term graft survival in adult kidney transplant participants in the Adherence Measurement in Stable Renal Transplant Patients Following Conversion From Prograf to Advagraf (ADMIRAD) clinical trial at 4 Belgian sites.
Article Synopsis
- The study aimed to evaluate the prevalence, severity, impact, and treatment options for vasomotor symptoms linked to menopause in East Asian women aged 40-65, utilizing a cross-sectional online survey.
- The survey revealed a prevalence rate of over 80% for vasomotor symptoms, with about 55% of women experiencing moderate to severe symptoms, and more than half of these women were untreated.
- It was found that treatment options were largely non-prescription, and only a small percentage were willing to use hormone therapy, highlighting a significant negative effect on health quality and daily activities for these women.
Background: Omalizumab, a humanised anti-immunoglobulin E monoclonal antibody for treatment of uncontrolled moderate-to-severe or severe persistent allergic asthma, was developed as a lyophilised powder for reconstitution. A liquid formulation in pre-filled syringes has now been developed. The purpose of this study was to assess the immunogenicity and safety of this liquid formulation.
View Article and Find Full Text PDFOmalizumab and the risk of malignancy: results from a pooled analysis.
J Allergy Clin Immunol
April 2012
Background: Since initial registration, the omalizumab clinical trial database has expanded considerably, with a doubling of patients exposed in the clinical trial environment. Previous pooled data (2003) from phase I to III studies of omalizumab showed a numeric imbalance in malignancies arising in omalizumab recipients (0.5%) compared with control subjects (0.
View Article and Find Full Text PDFBackground: Physicians have questioned whether omalizumab can be discontinued or the dose reduced after clinical improvement is seen in patients with severe asthma.
Objectives: To examine the relationships among omalizumab, free IgE, and clinical outcomes in a randomized, placebo-controlled trial in patients with severe persistent allergic asthma following a posology based on pretreatment total IgE and body weight.
Methods: A pharmacokinetic-pharmacodynamic binding model was used to calculate free IgE, omalizumab, and total IgE concentrations during the 28-week treatment and 16-week follow-up of the INvestigation of Omalizumab in seVere Asthma TrEatment (INNOVATE) study.